Holen Sie sich die Stockscreener-App
18.20
3.47%
-0.655
Handel nachbörslich:
18.20
Schlusskurs vom Vortag:
$18.86
Offen:
$18.9
24-Stunden-Volumen:
701.93K
Relative Volume:
1.08
Marktkapitalisierung:
$997.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.94%
1M Leistung:
+28.71%
6M Leistung:
+65.00%
1J Leistung:
-6.86%
1-Tages-Spanne:
$18.18
$19.18
1-Wochen-Bereich:
$16.89
$19.18
52-Wochen-Spanne:
$7.80
$22.68
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-468-4219
Adresse
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Vergleichen Sie BCAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.20 | 1.03B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Eingeleitet | Wells Fargo | Underweight |
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data - Yahoo Finance
Will Bicara Therapeutics Inc. stock sustain high P E ratios2025 Biggest Moves & Verified Entry Point Detection - Newser
Skandinaviska Enskilda Banken AB publ Acquires 61,201 Shares of Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) Stock Analysis Report | Financials & Insights - Benzinga
Does Bicara Therapeutics Inc (BCAX) offer a good opportunity for investors? - Setenews
Positive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating - TipRanks
Bicara’s ficerafusp alfa shows consistent response rates at lower dose By Investing.com - Investing.com Nigeria
Bicara Therapeutics (BCTX) Releases Promising Early Data from Ca - GuruFocus
Bicara’s ficerafusp alfa shows consistent response rates at lower dose - Investing.com
Bicara Therapeutics Announces Publication of an Abstract - GlobeNewswire
Buy Rating for Bicara Therapeutics Driven by Promising Efficacy and Safety of FICERA in ESMO Asia Abstract - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 3.3%Time to Sell? - MarketBeat
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN
What Analyst Ratings Reveal About Venus Pipes and Tubes Limiteds Future ValueShort-Term Trading Alerts & Turn Bull Runs into Life-Changing Wealth - earlytimes.in
What’s Bicara Therapeutics Inc (BCAX)’s Price to Earnings Ratio? - fostersleader.com
[424B5] Bicara Therapeutics Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock - Investing.com Nigeria
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $225,625.00 in Stock - MarketBeat
Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock By Investing.com - Investing.com South Africa
Bicara Therapeutics president Cohlhepp sells $225k in shares By Investing.com - Investing.com South Africa
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics president Cohlhepp sells $225k in shares - Investing.com
Bicara Therapeutics Executives Engage in Stock Sales - TradingView
Pres Cohlhepp Sells 12,500 ($225.6K) Of Bicara Therapeutics Inc [BCAX] - TradingView
Officer Raben Sells 11,000 ($205.1K) Of Bicara Therapeutics Inc [BCAX] - TradingView
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout (NASDAQ:BCAX) - Seeking Alpha
Ready to Jump After Recent Trade: Bicara Therapeutics Inc (BCAX) - Setenews
CFO Hyep Files To Sell 605 Of Bicara Therapeutics Inc [BCAX] - TradingView
How Bicara Therapeutics Inc. stock reacts to job market data2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com
Is Bicara Therapeutics Inc. stock safe for conservative investors - newser.com
Why Bicara Therapeutics Inc. stock appeals to analysts2025 Breakouts & Breakdowns & Reliable Momentum Entry Alerts - newser.com
What risks investors should watch in Bicara Therapeutics Inc. stock2025 EndofYear Setup & Consistent Income Trade Recommendations - newser.com
Should I hold or sell Bicara Therapeutics Inc. stock in 2025Insider Buying & Reliable Momentum Entry Alerts - newser.com
What dividend safety score for Bicara Therapeutics Inc. stockWall Street Watch & Long-Term Capital Growth Strategies - newser.com
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $29.67 Average Price Target from Analysts - Defense World
Analyzing Bicara Therapeutics Inc. with risk reward ratio chartsTrade Volume Report & High Conviction Buy Zone Picks - newser.com
Taking the lead: Bicara Therapeutics Inc (BCAX) - Setenews
Bicara Therapeutics (NASDAQ:BCAX) versus Senti Biosciences (NASDAQ:SNTI) Head to Head Analysis - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
How currency fluctuations impact Bicara Therapeutics Inc. stock2025 Market WrapUp & Accurate Buy Signal Alerts - newser.com
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Es liegen keine Finanzdaten für Bicara Therapeutics Inc (BCAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Bicara Therapeutics Inc-Aktie (BCAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hyep Ivan | Chief Financial Officer |
Nov 21 '25 |
Option Exercise |
3.79 |
605 |
2,293 |
145,960 |
| Hyep Ivan | Chief Financial Officer |
Nov 24 '25 |
Sale |
18.55 |
17,795 |
330,094 |
145,355 |
| Hyep Ivan | Chief Financial Officer |
Nov 21 '25 |
Sale |
18.15 |
605 |
10,981 |
145,355 |
| Cohlhepp Ryan | President and COO |
Nov 21 '25 |
Option Exercise |
3.79 |
8,000 |
30,318 |
206,141 |
| Cohlhepp Ryan | President and COO |
Nov 21 '25 |
Sale |
18.05 |
12,500 |
225,588 |
193,641 |
| Mazumdar Claire | Chief Executive Officer |
Nov 24 '25 |
Option Exercise |
3.79 |
41,163 |
156,000 |
351,055 |
| Mazumdar Claire | Chief Executive Officer |
Nov 24 '25 |
Sale |
18.86 |
41,163 |
776,429 |
309,892 |
| Raben David | Chief Medical Officer |
Nov 24 '25 |
Option Exercise |
3.79 |
5,500 |
20,844 |
40,997 |
| Raben David | Chief Medical Officer |
Nov 25 '25 |
Option Exercise |
3.79 |
5,500 |
20,844 |
40,091 |
| Raben David | Chief Medical Officer |
Nov 25 '25 |
Sale |
18.84 |
5,500 |
103,633 |
35,497 |
1.44%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):